Rossari Biotech Ltd
427.30
INR
+10.40
(+2.49%)
Rossari Biotech Ltd
NSE:ROSSARI
(National Stock Exchange of India)
Recent
price
427.30
P/E
ratio
19.73
div
yld
- -
ROIC.AI
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.- Similar Companies
- Business
- Rossari Biotech Limited manufactures and sells specialty chemicals primarily in India and internationally. The company offers a diversified portfolio of products including textile specialty chemicals such as enzymes and specialty chemicals for pre-treatment, dyeing, printing, finishing, cotton, polyester, acrylic, wool, silk, nylon, functional finishes, denim, and sustainable solutions; home and personal care ingredients encompassing polymers for detergents and cleaning, emulsions for paints and paper, performance enhancers for ceramics, and water treatment agents; animal health and nutrition solutions comprising poultry feed supplements, vitamin-mineral formulations, toxin binders, enzymes, acidifiers, trace minerals, essential oils, liquid nutraceuticals, and herbal preparations as well as pet grooming products like natural shampoos, powders, deodorants, sprays, creams, and floor washing liquids under brands including Lozalo, Hunger Fills, and Sniffy; and performance chemicals for soaps and detergents, inks, paints and coatings, ceramics and tiles, pulp and paper, cement, surfactants, aroma chemicals, cleaning, hygiene, disinfection, and institutional cleaning solutions. Founded in 1997 as Rossari Labtech and renamed Rossari Biotech Limited in 2003, the company is headquartered in Mumbai, Maharashtra, India, and operates manufacturing facilities including in Dahej with subsidiaries such as Unitop Chemicals Private Limited, Tristar Intermediates Private Limited, and Rossari International Limited Company in Saudi Arabia. Recent developments include the commissioning of additional 20,000 MTPA capacity at its Dahej facility and 15,000 MTPA ethoxylation capacity at Unitop in 2025, boosting total installed capacity to over 152,500 MTPA and supporting growth in personal care, agrochemicals, oil & gas, and pharma sectors; capacity expansions at subsidiaries Unitop by 18,500 MTPA and Tristar by 3,600 MTPA planned for completion by Q4 FY2025-26 at a cost of Rs 97 crore; and Board approval for up to USD 8 million investment in its wholly owned Saudi Arabian subsidiary to evaluate international expansion.